Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory for Complex, Severe, and Rare Diseases, Center for Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Skin Res Technol. 2024 Aug;30(8):e13900. doi: 10.1111/srt.13900.
CD8+ T cells have been recognized as crucial factors in the prognosis of melanoma. However, there is currently a lack of gene markers that accurately describe their characteristics and functions in acral melanoma (AM), which hinders the development of personalized medicine.
Firstly, we explored the composition differences of immune cells in AM using single-cell RNA sequencing (scRNA-seq) data and comprehensively characterized the immune microenvironment of AM in terms of composition, developmental differentiation, function, and cell communication. Subsequently, we constructed and validated a prognostic risk scoring model based on differentially expressed genes (DEGs) of CD8+ T cells using the TCGA-SKCM cohort through Lasso-Cox method. Lastly, immunofluorescence staining was performed to validate the expression of four genes (ISG20, CCL4, LPAR6, DDIT3) in AM and healthy skin tissues as included in the prognostic model.
The scRNA-seq data revealed that memory CD8+ T cells accounted for the highest proportion in the immune microenvironment of AM, reaching 70.5%. Cell-cell communication analysis showed extensive communication relationships among effector CD8+ T cells. Subsequently, we constructed a prognostic scoring model based on DEGs derived from CD8+ T cell sources. Four CD8+ T cell-related genes were included in the construction and validation of the prognostic model. Additionally, immunofluorescence results demonstrated that ISG20 and CCL4 were downregulated, while LPAR6 and DDIT3 were upregulated in AM tissues compared to normal skin tissues.
Identifying biomarkers based on the expression levels of CD8+ T cell-related genes may be an effective approach for establishing prognostic models in AM patients. The independently prognostic risk evaluation model we constructed provides new insights and theoretical support for immunotherapy in AM.
CD8+ T 细胞已被认为是黑色素瘤预后的关键因素。然而,目前缺乏能够准确描述肢端黑色素瘤(AM)中 CD8+ T 细胞特征和功能的基因标志物,这阻碍了个性化医疗的发展。
首先,我们使用单细胞 RNA 测序(scRNA-seq)数据探索 AM 中免疫细胞的组成差异,并从组成、发育分化、功能和细胞通讯等方面全面描述 AM 的免疫微环境。随后,我们使用 TCGA-SKCM 队列通过 Lasso-Cox 方法构建并验证了基于 CD8+ T 细胞差异表达基因(DEGs)的预后风险评分模型。最后,通过免疫荧光染色验证包括在预后模型中的四个基因(ISG20、CCL4、LPAR6、DDIT3)在 AM 和健康皮肤组织中的表达。
scRNA-seq 数据显示,记忆 CD8+ T 细胞在 AM 的免疫微环境中占比最高,达到 70.5%。细胞间通讯分析显示效应 CD8+ T 细胞之间存在广泛的通讯关系。随后,我们构建了一个基于 CD8+ T 细胞来源的 DEGs 的预后评分模型。四个 CD8+ T 细胞相关基因被纳入了预后模型的构建和验证中。此外,免疫荧光结果表明,与正常皮肤组织相比,AM 组织中 ISG20 和 CCL4 下调,而 LPAR6 和 DDIT3 上调。
基于 CD8+ T 细胞相关基因表达水平识别标志物可能是建立 AM 患者预后模型的有效方法。我们构建的独立预后风险评估模型为 AM 的免疫治疗提供了新的见解和理论支持。